

# Effectiveness of Transforaminal Epidural Steroid Injection by Using a Preganglionic Approach: A Prospective Randomized Controlled Study<sup>1</sup>

Hee Sun Jeong, MD  
Joon Woo Lee, MD  
Sung Hyun Kim, MD  
Jae Sung Myung, MD  
Joo Hyung Kim, MD  
Heung Sik Kang, MD

## Purpose:

To prospectively evaluate the short- and midterm effectiveness of transforaminal epidural steroid injection (TFESI) for lumbosacral radiculopathy with respect to injection level.

## Materials and Methods:

Institutional review board approval and written informed consent were obtained. From March 2005 to February 2006, 239 consecutive patients (106 male, 133 female; mean age, 49.8 years; range, 13–82 years) who were scheduled to undergo lumbar TFESI were enrolled. The patients were randomly assigned to either the ganglionic (TFESI at the location of the exiting nerve root) or preganglionic group (TFESI at the supraadjacent intervertebral disk level). Follow-up was conducted within 1 month (short term) and more than 6 months (midterm) after injections. Short- and midterm outcomes were measured by using a visual analog scale and a four-grade scale. Univariate analysis (by using the Fisher exact and  $\chi^2$  tests) and multiple logistic regression analysis were performed to evaluate the relationship between possible outcome predictors (ganglionic or preganglionic injection levels, cause of radiculopathy, duration of symptoms, age group, and sex) and the therapeutic effect.

## Results:

Univariate analysis showed that the preganglionic group had a better treatment effect (99 of 112, 88.4%) than did the ganglionic group (90 of 127, 70.9%) at short-term follow-up ( $P = .001$ ). Multiple logistic regression analysis showed that the only significant outcome predictor at short-term follow-up was injection level (odds ratio = 2.232,  $P = .037$ ). No significant difference was identified regarding TFESI approach or cause of radiculopathy at midterm follow-up.

## Conclusion:

TFESI for lumbosacral radiculopathy with a preganglionic approach is more effective than TFESI with a ganglionic approach at short-term follow-up.

© RSNA, 2007

<sup>1</sup> From the Department of Radiology, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707 Seoul, Korea. Received November 24, 2006; revision requested January 24, 2007; revision received February 12; accepted March 17; final version accepted May 11. Address correspondence to J.W.L. (e-mail: joonwoo@radiol.snu.ac.kr).

Lumbosacral radiculopathy is a common medical and socioeconomic problem (1–3), with a lifetime prevalence estimated to be around 40%–60% (4–5). Intervertebral disk herniation and degenerative lumbar spinal stenosis are the two most common causes of lumbosacral radiculopathy (1,6–9).

Lumbar transforaminal epidural steroid injection (TFESI) is a procedure designed to deliver an aliquot of a corticosteroid preparation to the immediate vicinity of a lumbar spinal nerve and its root via the intervertebral foramen in which the target nerve lies (10). Compared with an interlaminar or caudal epidural steroid injection, a transforaminal approach provides minimal risk of dural puncture, better delivery of medication to the site of radiculopathy, and increased spread into the ventral epidural space. Subsequently, only a low volume of concentrated medication is necessary to produce the desired effect (11–13). Currently, TFESI is widely used for the management of lumbosacral radiculopathy (10,13).

In our daily practice, when we encountered nerve root compression caused by either subarticular or paracentral disk herniation or central canal and/or lateral recess stenosis supraadjacent to the intervertebral disk, we frequently wondered whether TFESI should be performed at the neural foramen near the exit zone of the compressed nerve root (eg, at the L5-S1 neural foramen for an L5 nerve root compressed at the L4-5 disk) or at the neural foramen near the compression level (eg, at the L4-5 neural foramen for an L5 nerve root compressed at the L4-5 disk). The latter has been called the “preganglionic ap-

proach” (14). There is no clear-cut consensus regarding the ideal injection level to perform TFESI in these situations, and determination of the injection level appears to rely heavily on personal experience.

Lee et al (15) evaluated the effectiveness of TFESI by using a preganglionic approach for treating lumbosacral radiculopathy when the nerve root compression was located supraadjacent to the intervertebral disk. To our knowledge, Lee et al conducted the only comparative study that has assessed the effectiveness of TFESI with respect to injection level. However, the study by Lee et al was retrospective, used a small number of patients, and focused only on short-term therapeutic effect. Thus, the purpose of our study was to prospectively evaluate the short- and midterm effectiveness of TFESI for lumbosacral radiculopathy with respect to the injection level.

## Materials and Methods

### Patients

Institutional review board approval and written informed consent were obtained for this study. During a 1-year period from March 2005 to February 2006, 239 consecutive patients (106 male and 133 female patients; mean age, 49.8 years; range, 13–82 years) who underwent lumbar TFESI at our radiology department were enrolled in our prospective study, having met the following inclusion criteria: (a) the presence of lumbosacral radiculopathy, (b) clear documentation of nerve root compression with either subarticular

or paracentral disk herniation or central canal and/or lateral recess stenosis at the supraadjacent intervertebral disk (eg, L5 nerve root compressed at L4-5 disk) by using clinical and cross-sectional imaging studies (either computed tomography [CT] or magnetic resonance [MR] imaging) with consensus of three radiologists, and (c) one-level TFESI from L1 to S1.

The patients were randomly assigned to either the ganglionic or the preganglionic group on the basis of the neural foramen level of the injection (Fig 1). Patients in the ganglionic group underwent TFESI at the location of the exiting nerve root (eg, TFESI for L5 radiculopathy was performed at L5-S1 neural foramen, when L5 nerve root impingement was at the L4-5 disk). In the preganglionic group, patients underwent TFESI at the supraadjacent intervertebral disk level (for example, at L4-5 neural foramen for an L5 nerve root compression). The ganglionic group included 127 patients (61 male and 66 female patients; mean age, 49 years; range, 15–82 years) and the preganglionic group included 112 patients (45 male and 67 female patients; mean age, 50 years; range, 13–78 years).

All patients underwent short-term follow-up within 1 month after injections (mean interval, 15 days; range, 7–30 days). Outcomes were measured by using a visual analog scale (VAS) and a four-grade scale (see below)

### Advance in Knowledge

- The use of transforaminal epidural steroid injection with a preganglionic approach is more effective (99 of 112 patients) than a ganglionic approach (90 of 127 patients) at short-term follow-up and is almost as effective (64 of 106 patients) as a ganglionic approach (80 of 116 patients) at midterm follow-up.

### Implication for Patient Care

- A preganglionic approach may be considered an alternative to a ganglionic approach when the needle tip cannot be advanced adjacent to the neural foramen or when adequate amounts of the drug cannot be injected into the epidural space through the neural foramen owing to severe neural foraminal stenosis.

### Published online

10.1148/radiol.2452062007

Radiology 2007; 245:584–590

### Abbreviations:

TFESI = transforaminal epidural steroid injection

VAS = visual analog scale

### Author contributions:

Guarantor of integrity of entire study, J.W.L.; study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; approval of final version of submitted manuscript, all authors; literature research, H.S.J., J.S.M., J.H.K.; clinical studies, H.S.J., J.W.L., S.H.K., J.S.M.; statistical analysis, J.W.L.; and manuscript editing, J.W.L., S.H.K., J.H.K., H.S.K.

Authors stated no financial relationship to disclose.

(7,16,17). By September 2006, more than 6 months after injections, midterm follow-up (mean interval, 373 days; range, 216–547 days) interviews were conducted by telephone (see below) by using the VAS and four-grade scale. VAS forms were mailed or faxed to patients. Out of 239 patients, 17 were lost to midterm follow-up.

### Injection Technique

TFESIs were performed in our department by three radiologists (S.H.K., J.W.L., and H.S.J., with 5, 3, and 2 years experience in spine injections, respectively). The injections were performed in an angiography suite equipped with biplanar fluoroscopy while the patient lay prone.

After sterile preparation, draping, and local anesthesia with 1% lidocaine, a 12-cm-long, 22-gauge spinal needle was advanced into the region of the involved nerve root by using fluoroscopic guidance. The target point was around the neural foramen. The needle position was checked by using biplanar fluoroscopy. Next, approximately 1 mL of contrast material (Omnipaque 300 [iohexol, 300 mg iodine per milliliter]; Amersham Health, Princeton, NJ) was injected to confirm epidural flow and to avoid intravascular, intradural, or soft-tissue infiltration. Bupivacaine hydrochloride (0.5 mL, Marcaine Spinal 0.5% Heavy; AstraZeneca, Westborough, Mass) and 40 mg (1 mL) of triamcinolone acetonide suspension (Tamce-ton [40 mg per milliliter]; Hanall Pharmaceutical, Seoul, Korea) were slowly injected. Posteroanterior and lateral spot radiographs were obtained to document distribution of the contrast material.

According to Lew et al (14), the fluoroscopic landmarks for the preganglionic approach are similar to those used for intradisk procedures (lateral to the superior articular process and parallel to the superior endplate of the vertebral body). The final needle position is at the inferior aspect of the supraadjacent neural foramen, with the bevel immediately dorsal to the annulus and/or posterior longitudinal ligament. Injection at this position places the aliquot at the

epidural preganglionic site of neural impingement, where the traversing nerve root is closest to the disk. The injectant may also descend to the intraforaminal and epidural portions of the exiting nerve root. Lee et al (15) modified this method. The landmark they used for needle insertion is just lateral to the pars interarticularis on the oblique view and at the neural foramen near the nerve root impingement site at the supraadjacent disk level. We used this modified method by Lee et al for the preganglionic approach (Fig 2).



### Clinical Assessment

Before the injection, one of two radiologists (S.H.K., J.W.L.) recorded the duration of symptoms, level, and cause of nerve root impingement on the CT or MR images and the affected dermatomal distribution on the medical charts.

Patient outcomes were assessed within 1 month (short term) by another radiologist who was blinded to the injection level (ganglionic or preganglionic) by using a VAS that ranged from 0 to 100 and a four-grade scale that was subjectively expressed by the patients with regard to the degree of improvement (excellent, good, fair, or poor) (2,7,11). The patients were also not informed of the injection method to ensure a double-blinded protocol for our study. The patients with a reduction in the VAS of more than 50% after the injection and with excellent or good improvement were classified as receiving effective

treatment, and the patients with a reduction in the VAS of less than 50% after the injection and with fair or poor improvement were classified as having ineffective treatment.

Midterm outcome was assessed in September 2006 by telephone interview more than 6 months (mean interval, 373 days; range, 216–547 days) after injections. A nurse who did not know the injection level (ganglionic or preganglionic) queried the patients in the same manner as for the short-term follow-up by using a VAS and a four-grade scale. Midterm results were similarly classi-



fied as either effective or ineffective treatment.

### Statistical Analysis

The patients were divided into six age groups for statistical analysis: aged 29 years or younger, 30–39, 40–49, 50–59, 60–69, and 70 years or older (1). The duration of symptoms was classi-

fied as less than or more than 6 months (15,17).

The Mann-Whitney *U* test was used to evaluate for age differences between the ganglionic and the preganglionic group. The Fisher exact test was used to analyze differences in sex, cause of radiculopathy, and duration of symptoms between the two patient groups.

Univariate analysis was performed to evaluate the relationship between possible outcome predictors and the therapeutic effect by using the Fisher exact test and the  $\chi^2$  test. Fisher exact tests were used for the injection level, cause of radiculopathy, symptom duration, and sex. The  $\chi^2$  test was used for age groups. Multiple logistic regression analysis was also performed to evaluate the relationship between possible outcome predictors and their therapeutic effects. Analyses were performed for both short- and midterm therapeutic effect. Data were analyzed by using a software program (SPSS, version 10.0; SPSS, Chicago, Ill). A *P* value of less than .05 was considered to indicate a significant difference.

**Table 1**

#### Comparison of Ganglionic and Preganglionic Groups

Characteristic	Ganglionic ( <i>n</i> = 127)	Preganglionic ( <i>n</i> = 112)	<i>P</i> Value
Age group (y)			
<29	19 (15.0)	13 (11.6)	.542
30–39	18 (14.2)	16 (14.3)	
40–49	23 (18.1)	22 (19.6)	
50–59	24 (18.9)	27 (24.1)	
60–69	22 (17.3)	24 (21.4)	
70>	21 (16.5)	10 (8.9)	
Sex			
Male	61 (48.0)	45 (40.2)	.242
Female	66 (52.0)	67 (59.8)	
Cause of radiculopathy			
Spinal stenosis	23 (18.1)	23 (20.5)	.743
Intervertebral herniated disc	104 (81.9)	89 (79.5)	
Duration of symptoms (mo)			
<6	81 (63.8)	63 (56.3)	.289
>6	46 (36.2)	49 (43.7)	

Note.—Data are number of patients. Numbers in parentheses are percentages.

**Table 2**

#### Four-Grade Scale at Short-term Follow-up

TFESI Approach	Excellent	Good	Fair	Poor
Ganglionic ( <i>n</i> = 127)	59 (46.5)	31 (24.4)	17 (13.4)	20 (15.7)
Preganglionic ( <i>n</i> = 112)	82 (73.2)	17 (15.2)	2 (1.8)	11 (9.8)

Note.—Data are number of patients. Numbers in parentheses are percentages.

**Table 3**

#### Four-Grade Scale at Midterm Follow-up

TFESI Approach	Excellent	Good	Fair	Poor
Ganglionic ( <i>n</i> = 116)	39 (33.6)	39 (33.6)	2 (1.7)	36 (31.1)
Preganglionic ( <i>n</i> = 106)	39 (36.8)	25 (23.6)	4 (3.8)	38 (35.8)

Note.—Data are number of patients. Numbers in parentheses are percentages.

### Results

There were no significant differences between the ganglionic and the preganglionic group with respect to age (*P* = .542) and sex (*P* = .242). Age was 49.1 years  $\pm$  17.6 (mean age  $\pm$  standard deviation) in the ganglionic group and 50.5 years  $\pm$  17.4 in the preganglionic group. There were no significant differences between the two groups with respect to cause of radiculopathy and duration of symptoms (Table 1). In the ganglionic group, TFESIs at L5-S1 were performed in 42 patients, at L4-5 in 74 patients, at L3-4 in eight patients, and at L2-3 in three patients. In the preganglionic group, TFESIs were performed at L5-S1 in 49 patients, at L4-5 in 58 patients, at L3-4 in three patients, and at L2-3 in two patients. There were no reported complications of dural puncture, nerve root injury, excessive bleeding, or infection.

#### Short-term and Midterm Results

At short-term follow-up, the preganglionic group had more patients with excellent results (82 of 112, 73.2%) than did the ganglionic group (59 of 127, 46.5%) (Tables 2, 3). However, at midterm follow-up, there was little difference in the number of patients with excellent results between the two groups.

Univariate analysis showed that the preganglionic group had better thera-

peutic effect (99 of 112, 88.4%) than did the ganglionic group (90 of 127, 70.9%) at short-term follow-up ( $P = .001$ ) (Tables 4, 5). Multiple logistic regression analysis showed that the only significant outcome predictor at short-term follow-up was the injection level (ganglionic or preganglionic) (odds ratio = 2.232,  $P = .037$ ). The cause of radiculopathy showed borderline significance at short-term follow-up (odds ratio = 3.460,  $P = .052$ ) according to multiple logistic regression analysis.

No significant differences were identified regarding the injection level or the cause of radiculopathy at midterm follow-up (Tables 6, 7) by using univariate and multiple logistic regression analyses, contrary to the short-term results. At univariate analysis, patients with symptom duration of less than 6 months had better therapeutic effect than did those with symptom duration of more than 6 months at midterm follow-up. Multiple logistic regression analysis did not show a significant relationship between symptom duration and therapeutic effect at midterm follow-up.

## Discussion

According to our prospective randomized study, TFESI with a preganglionic approach was more effective than a ganglionic approach at short-term follow-up. These results were similar to those of Lee et al (15). This finding supports the idea that TFESI, by using a preganglionic technique, can place the injectant closer to the site of neural impingement and allow the delivery of medicine more directly to reduce inflammation and relieve pain (14,16). The preganglionic approach may be considered an alternative to the ganglionic approach when the needle tip cannot be advanced evenly adjacent to the neural foramen or adequate amounts of the drug cannot be injected into the epidural space through the neural foramen owing to severe neural foraminal stenosis. Another advantage of the preganglionic approach is that the injectant distributes itself predominantly in the epidural space at the disk level (15).

Lew et al (14) suggested a TFESI

**Table 4**

### Univariate Analysis of Possible Outcome Predictors for TFESI Effectiveness at Short-term Follow-up

Characteristic	Effective ( <i>n</i> = 189)	Ineffective ( <i>n</i> = 50)	<i>P</i> Value
TFESI Approach			.001
Ganglionic	90 (47.6)	37 (74)	
Preganglionic	99 (52.4)	13 (26)	
Cause of radiculopathy			.162
Spinal stenosis	41 (21.7)	6 (12.0)	
Intervertebral herniated disc	148 (78.3)	44 (88.0)	
Age group (y)			.383
<29	22 (12.2)	9 (23.7)	
30–39	23 (12.8)	7 (18.4)	
40–49	38 (21.1)	5 (13.2)	
50–59	35 (19.4)	7 (18.4)	
60–69	37 (20.6)	6 (15.8)	
70>	25 (13.9)	4 (10.5)	
Sex			.263
Male	80 (42.3)	26 (52.0)	
Female	109 (57.7)	24 (48.0)	

Note.—Data are number of patients. Numbers in parentheses are percentages.

**Table 5**

### Multiple Logistic Regression Analysis for Possible Outcome Predictors for TFESI Effectiveness at Short-term Follow-up

Characteristic	Regression Coefficient*	Standard Error	Wald Statistic	<i>P</i> Value	Odds Ratio
TFESI approach	0.803	0.385	3.783	.037	2.232
Cause of radiculopathy	1.241	0.638	3.783	.052	3.460
Age group	−0.203	0.119	2.895	.089	0.816
Sex	−0.397	0.377	1.106	.293	0.672
Duration of symptoms	0.090	0.397	0.051	.821	1.094
Constant	−4.335	1.642	6.967	.008	0.013

\* *df* = 1 for all comparisons.

approach similar to that used for standard lumbar discography. There were two other studies (16,18) in which the therapeutic effect of the TFESI approach by using the anatomic landmarks for intradisk procedures was reported. However, those two studies focused only on the injection technique, and not on the injection level.

For the preganglionic approach, Lee et al (15) modified the injection technique in a manner similar to the retroneural technique described by the International Spine Intervention Society

(10). The objective of the retroneural technique is to place the tip of the needle immediately dorsal to, but not in, the spinal nerve (10). We used the retroneural technique for the preganglionic approach. From our experience, the TFESI approach similar to that used for standard lumbar discography may carry a higher risk of intradisk placement of contrast medium. This is important to identify because serious potential complications, such as diskitis, may occur (19). By using the retroneural technique, we could deposit most of the

injectant into the epidural space and avoid placing the injectant directly in the spinal nerve. This technique also enabled us to avoid pricking the nerve root.

According to our results, there was no significant difference in therapeutic effect due to symptom duration at short-term follow-up. Interestingly, shorter symptom duration favors a better outcome than does longer symptom dura-

tion at midterm follow-up. This may mean that the patients with longer symptom duration have a tendency toward experiencing recurrent pain attacks. Patients with spinal stenosis exhibited a similar therapeutic effect when compared with those who had intervertebral herniated disc at short-term follow-up (41 of 47, 87.2%). Our results regarding spinal stenosis at short-term follow-up showed a higher success rate

than did those of previous reports (6,9,20) and were in discord with the results of one comparative study (9).

One criticism of epidural steroid injections is that their benefit lasts only for a short duration (21–24). Ridley et al (21) reported that the therapeutic benefits disappeared within 6 months of treatment. However, we achieved a success rate of 69.0% in the ganglionic group and 60.4% in the preganglionic group at the follow-up interval of more than 6 months. Lutz et al (17) showed that 75.4% of patients who underwent TFESI also had a successful midterm outcome at an average follow-up of 20 months. Other previous prospective randomized trials studying the effectiveness of TFESI concluded that these injections can provide positive long-term relief (1,25).

In our study, an interesting point was that at short-term follow-up the outcome was ineffective, but by midterm follow-up the outcome was effective for 32 patients. This result may suggest that in some situations, the patient's symptoms can improve due to spontaneous regression of inflammation around the nerve root.

Our study had several limitations. First, this study did not evaluate if other factors such as physical examination findings, patient mood, general health, smoking status, or the frequency of injections might influence therapeutic effectiveness and are correlated with outcomes. This study focused on the influence of the injection level on the therapeutic effect after TFESI. Second, patient outcome was measured only with a pain score and not according to physical function. However, the most appropriate goal for TFESI may be pain reduction, not functional restoration. Third, follow-up was less than 1 year, which did not include a long-term period. However, in our opinion, the midterm follow-up is enough to evaluate the influence of injection level on the therapeutic effect.

In conclusion, the results of our study indicate that use of TFESI with a preganglionic approach is more effective than a ganglionic approach at short-term follow-up and is almost as effective

**Table 6**

**Univariate Analysis for Possible Outcome Predictors for TFESI Effectiveness at Midterm Follow-up**

Characteristic	Effective ( <i>n</i> = 144)	Ineffective ( <i>n</i> = 78)	<i>P</i> Value
TFESI approach			.206
Ganglionic	80 (55.6)	36 (46.2)	
Preganglionic	64 (44.4)	42 (53.8)	
Cause of radiculopathy			.382
Spinal stenosis	26 (18.1)	18 (23.1)	
Intervertebral herniated disc	118 (81.9)	60 (76.9)	
Age group (y)			.670
<29	18 (13.4)	13 (18.8)	
30–39	15 (11.2)	11 (15.9)	
40–49	28 (20.9)	13 (18.8)	
50–59	28 (20.9)	11 (15.9)	
60–69	25 (18.7)	14 (20.3)	
70>	20 (14.9)	7 (10.1)	
Sex			.322
Male	66 (45.8)	30 (38.5)	
Female	78 (54.2)	48 (61.5)	
Duration of symptoms (mo)			.010
<6	96 (66.7)	38 (48.7)	
>6	48 (33.3)	40 (51.3)	

Note.—Data are number of patients. Numbers in parentheses are percentages.

**Table 7**

**Multiple Logistic Regression Analysis for Possible Outcome Predictors for TFESI Effectiveness at Midterm Follow-up**

Characteristic	Regression Coefficient*	Standard Error	Wald Statistics	<i>P</i> Value	Odds Ratio
TFESI approach	−0.462	0.309	2.230	.135	0.630
Cause of radiculopathy	−0.156	0.372	0.177	.674	0.855
Age group	−0.100	0.095	1.115	.291	0.905
Sex	0.260	0.315	0.682	.409	1.297
Duration of symptoms	0.541	0.314	2.967	.085	1.718
Constant	−0.276	1.086	0.064	.800	0.759

\* *df* = 1 for all comparisons.

as a ganglionic approach at midterm follow-up.

## References

- Vad VB, Bhat AL, Lutz GE, Cammisa F. Transforaminal epidural steroid injections in lumbosacral radiculopathy. *Spine* 2002;27:11–16.
- Silbergleit R, Mehta BA, Sanders WP, Talati SJ. Imaging-guided injection techniques with fluoroscopy and CT for spinal pain management. *RadioGraphics* 2001;21:927–942.
- McLain RF. Lumbar disc disease. In: Frymoyer JW, Wiesel SW, eds. *The adult and pediatric spine*. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2004; 929–944.
- Tong HC, Williams JC, Haig AJ, Geisser ME, Chiodo A. Predicting outcomes of transforaminal epidural injections for sciatica. *Spine J* 2003;3:430–434.
- Pfirschmann CW, Oberholzer PA, Zanetti M, et al. Selective nerve root blocks for the treatment of sciatica: evaluation of injection site and effectiveness—a study with patients and cadavers. *Radiology* 2001;221:704–711.
- Botwin KP, Gruber RD, Bouchlas CG, et al. Fluoroscopically guided lumbar transforaminal epidural steroid injections in degenerative lumbar stenosis: an outcome study. *Am J Phys Med Rehabil* 2002;81:898–905.
- Cyteval C, Fescquet N, Thomas E, Decoux E, Blotman F, Taourel P. Predictive factors of efficacy of periradicular corticosteroid injections for lumbar radiculopathy. *AJNR Am J Neuroradiol* 2006;27:978–982.
- Boswell MV, Hansen HC, Trescot AM, Hirsch JA. Epidural steroids in the management of chronic spinal pain and radiculopathy. *Pain Physician* 2003;6:319–334.
- Rosenberg SK, Grabinsky A, Kooser C, Boswell MV. Effectiveness of transforaminal epidural steroid injections in low back pain: a 1-year experience. *Pain Physician* 2002;5:266–270.
- Bogduk N. Lumbar transforaminal injection of corticosteroids. In: *Practice guidelines for spinal diagnostic and treatment procedures*. San Francisco, Calif: International Spine Intervention Society, 2004; 163–187.
- Cluff R, Mehio AK, Cohen SP, Chang Y, Sang CN, Stojanovic MP. The technical aspects of epidural steroid injections: a national survey. *Anesth Analg* 2002;95:403–408.
- Fenton DS, Czervionke LF. Selective nerve root block. In: *Image-guided spine intervention*. Philadelphia, Pa: Saunders, 2003; 73–98.
- Manchikanti L. Transforaminal lumbar epidural steroid injections. *Pain Physician* 2000;3:374–398.
- Lew HL, Coelho P, Chou LH. Preganglionic approach to transforaminal epidural steroid injections. *Am J Phys Med Rehabil* 2004;83:378.
- Lee JW, Kim SH, Choi JY, et al. Transforaminal epidural steroid injection for lumbosacral radiculopathy: preganglionic versus conventional approach. *Korean J Radiol* 2006;7:139–144.
- Yang SC, Fu TS, Lai PL, Niu CC, Chen LH, Chen WJ. Transforaminal epidural steroid injection for discectomy candidates: an outcome study with a minimum of 2-year follow-up. *Chang Gung Med J* 2006;29:93–99.
- Lutz GE, Vad VB, Wisneski RJ. Fluoroscopic transforaminal lumbar epidural steroids: an outcome study. *Arch Phys Med Rehabil* 1998;79:1362–1366.
- Lee KS, Lin CL, Hwang SL, Hwang SL, Wang CK. Transforaminal periradicular infiltration guided by CT for unilateral sciatica: an outcome study. *Clin Imaging* 2005;29:211–214.
- Finn KP, Case JL. Disk entry: a complication of transforaminal epidural injection—a case report. *Arch Phys Med Rehabil* 2005;86:1489–1491.
- Delpont EG, Cucuzzella AR, Marley JK, Pruitt CM, Fisher JR. Treatment of lumbar spinal stenosis with epidural steroid injections: a retrospective outcome study. *Arch Phys Med Rehabil* 2004;85:479–484.
- Ridley MG, Kingsley GH, Gibson T, Grahame R. Outpatient lumbar epidural corticosteroid injection in the management of sciatica. *Br J Rheumatol* 1988;27:295–299.
- Bogduk N. Spine update: epidural steroids. *Spine* 1995;20:845–848.
- Koes BW, Scholten RJ, Mens JM, Bouter LM. Efficacy of epidural steroid injections for low-back pain and sciatica: a systematic review of randomized clinical trials. *Pain* 1995;63:279–288.
- Karppinen J, Malmivaara A, Kurunlahti M, et al. Cost effectiveness of periradicular infiltration for sciatica. *Spine* 2001;26:1059–1067.
- Riew KD, Yin Y, Gilula L, et al. The effect of nerve-root injections on the need for operative treatment of lumbar radicular pain. *J Bone Joint Surg Am* 2000;82-A:1589–1593.

# Radiology 2007

## This is your reprint order form or pro forma invoice

(Please keep a copy of this document for your records.)

Reprint order forms and purchase orders or prepayments must be received 72 hours after receipt of form either by mail or by fax at 410-820-9765. It is the policy of Cadmus Reprints to issue one invoice per order.

**Please print clearly.**

Author Name \_\_\_\_\_  
Title of Article \_\_\_\_\_  
Issue of Journal \_\_\_\_\_ Reprint # \_\_\_\_\_ Publication Date \_\_\_\_\_  
Number of Pages \_\_\_\_\_ KB # \_\_\_\_\_ Symbol Radiology  
Color in Article? Yes / No (Please Circle)

**Please include the journal name and reprint number or manuscript number on your purchase order or other correspondence.**

### Order and Shipping Information

#### Reprint Costs (Please see page 2 of 2 for reprint costs/fees.)

\_\_\_\_\_ Number of reprints ordered \$ \_\_\_\_\_  
\_\_\_\_\_ Number of color reprints ordered \$ \_\_\_\_\_  
\_\_\_\_\_ Number of covers ordered \$ \_\_\_\_\_  
**Subtotal** \$ \_\_\_\_\_  
Taxes \$ \_\_\_\_\_

*(Add appropriate sales tax for Virginia, Maryland, Pennsylvania, and the District of Columbia or Canadian GST to the reprints if your order is to be shipped to these locations.)*

First address included, add \$32 for  
each additional shipping address \$ \_\_\_\_\_

**TOTAL** \$ \_\_\_\_\_

#### Shipping Address (cannot ship to a P.O. Box) Please Print Clearly

Name \_\_\_\_\_  
Institution \_\_\_\_\_  
Street \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
Country \_\_\_\_\_  
Quantity \_\_\_\_\_ Fax \_\_\_\_\_  
Phone: Day \_\_\_\_\_ Evening \_\_\_\_\_  
E-mail Address \_\_\_\_\_

#### Additional Shipping Address\* (cannot ship to a P.O. Box)

Name \_\_\_\_\_  
Institution \_\_\_\_\_  
Street \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
Country \_\_\_\_\_  
Quantity \_\_\_\_\_ Fax \_\_\_\_\_  
Phone: Day \_\_\_\_\_ Evening \_\_\_\_\_  
E-mail Address \_\_\_\_\_

\* Add \$32 for each additional shipping address

### Payment and Credit Card Details

Enclosed: Personal Check \_\_\_\_\_  
Credit Card Payment Details \_\_\_\_\_

Checks must be paid in U.S. dollars and drawn on a U.S. Bank.

Credit Card:  VISA  Am. Exp.  MasterCard

Card Number \_\_\_\_\_

Expiration Date \_\_\_\_\_

Signature: \_\_\_\_\_

Please send your order form and prepayment made payable to:

**Cadmus Reprints**

**P.O. Box 751903**

**Charlotte, NC 28275-1903**

**Note: Do not send express packages to this location, PO Box.**  
FEIN #: 541274108

Signature \_\_\_\_\_

Date \_\_\_\_\_

Signature is required. By signing this form, the author agrees to accept the responsibility for the payment of reprints and/or all charges described in this document.

### Invoice or Credit Card Information

#### Invoice Address Please Print Clearly

Please complete Invoice address as it appears on credit card statement

Name \_\_\_\_\_  
Institution \_\_\_\_\_  
Department \_\_\_\_\_  
Street \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
Country \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
E-mail Address \_\_\_\_\_

**Cadmus will process credit cards and Cadmus Journal Services will appear on the credit card statement.**

*If you don't mail your order form, you may fax it to 410-820-9765 with your credit card information.*

# Radiology 2007

## Black and White Reprint Prices

Domestic (USA only)						
# of Pages	50	100	200	300	400	500
1-4	\$213	\$228	\$260	\$278	\$295	\$313
5-8	\$338	\$373	\$420	\$453	\$495	\$530
9-12	\$450	\$500	\$575	\$635	\$693	\$755
13-16	\$555	\$623	\$728	\$805	\$888	\$965
17-20	\$673	\$753	\$883	\$990	\$1,085	\$1,185
21-24	\$785	\$880	\$1,040	\$1,165	\$1,285	\$1,413
25-28	\$895	\$1,010	\$1,208	\$1,350	\$1,498	\$1,638
29-32	\$1,008	\$1,143	\$1,363	\$1,525	\$1,698	\$1,865
Covers	\$95	\$118	\$218	\$320	\$428	\$530

## Color Reprint Prices

Domestic (USA only)						
# of Pages	50	100	200	300	400	500
1-4	\$218	\$233	\$343	\$460	\$579	\$697
5-8	\$343	\$388	\$584	\$825	\$1,069	\$1,311
9-12	\$471	\$503	\$828	\$1,196	\$1,563	\$1,935
13-16	\$601	\$633	\$1,073	\$1,562	\$2,058	\$2,547
17-20	\$738	\$767	\$1,319	\$1,940	\$2,550	\$3,164
21-24	\$872	\$899	\$1,564	\$2,308	\$3,045	\$3,790
25-28	\$1,004	\$1,035	\$1,820	\$2,678	\$3,545	\$4,403
29-32	\$1,140	\$1,173	\$2,063	\$3,048	\$4,040	\$5,028
Covers	\$95	\$118	\$218	\$320	\$428	\$530

International (includes Canada and Mexico)						
# of Pages	50	100	200	300	400	500
1-4	\$263	\$275	\$330	\$385	\$430	\$485
5-8	\$415	\$443	\$555	\$650	\$753	\$850
9-12	\$563	\$608	\$773	\$930	\$1,070	\$1,228
13-16	\$698	\$760	\$988	\$1,185	\$1,388	\$1,585
17-20	\$848	\$925	\$1,203	\$1,463	\$1,705	\$1,950
21-24	\$985	\$1,080	\$1,420	\$1,725	\$2,025	\$2,325
25-28	\$1,135	\$1,248	\$1,640	\$1,990	\$2,350	\$2,698
29-32	\$1,273	\$1,403	\$1,863	\$2,265	\$2,673	\$3,075
Covers	\$148	\$168	\$308	\$463	\$615	\$768

International (includes Canada and Mexico)						
# of Pages	50	100	200	300	400	500
1-4	\$268	\$280	\$412	\$568	\$715	\$871
5-8	\$419	\$457	\$720	\$1,022	\$1,328	\$1,633
9-12	\$583	\$610	\$1,025	\$1,492	\$1,941	\$2,407
13-16	\$742	\$770	\$1,333	\$1,943	\$2,556	\$3,167
17-20	\$913	\$941	\$1,641	\$2,412	\$3,169	\$3,929
21-24	\$1,072	\$1,100	\$1,946	\$2,867	\$3,785	\$4,703
25-28	\$1,246	\$1,274	\$2,254	\$3,318	\$4,398	\$5,463
29-32	\$1,405	\$1,433	\$2,561	\$3,788	\$5,014	\$6,237
Covers	\$148	\$168	\$308	\$463	\$615	\$768

Minimum order is 50 copies. For orders larger than 500 copies, please consult Cadmus Reprints at 800-407-9190.

### Reprint Cover

Cover prices are listed above. The cover will include the publication title, article title, and author name in black.

### Shipping

Shipping costs are included in the reprint prices. Domestic orders are shipped via UPS Ground service. Foreign orders are shipped via a proof of delivery air service.

### Multiple Shipments

Orders can be shipped to more than one location. Please be aware that it will cost \$32 for each additional location.

### Delivery

Your order will be shipped within 2 weeks of the journal print date. Allow extra time for delivery.

### Tax Due

Residents of Virginia, Maryland, Pennsylvania, and the District of Columbia are required to add the appropriate sales tax to each reprint order. For orders shipped to Canada, please add 7% Canadian GST unless exemption is claimed.

### Ordering

Reprint order forms and purchase order or prepayment is required to process your order. Please reference journal name and reprint number or manuscript number on any correspondence. You may use the reverse side of this form as a proforma invoice. Please return your order form and prepayment to:

#### Cadmus Reprints

P.O. Box 751903  
Charlotte, NC 28275-1903

**Note: Do not send express packages to this location, PO Box. FEIN #: 541274108**

Please direct all inquiries to:

**Rose A. Baynard**  
800-407-9190 (toll free number)  
410-819-3966 (direct number)  
410-820-9765 (FAX number)  
[baynardr@cadmus.com](mailto:baynardr@cadmus.com) (e-mail)

**Reprint Order Forms and purchase order or prepayments must be received 72 hours after receipt of form.**